ChemAesthetic Retatrutide is a high-purity research peptide formulated for advanced studies in metabolism, obesity and diabetes. Supplied in 10 mg and 30 mg lyophilized vials (with sterile bacteriostatic water), it constitutes a triple hormone receptor agonist that activates the GIP, GLP-1 and glucagon receptors
. This once-weekly peptide (LY3437943) is under investigation for weight and glycaemic control. In a 48-week Phase 2 obesity trial, retatrutide achieved up to ~24.2% mean body-weight reduction at the highest dose
, far exceeding the effects of earlier GLP-1-only drugs. ChemAesthetic’s Retatrutide is sold strictly for laboratory research use only (not for human or veterinary use)
. All information on this page is for educational and research reference.
ChemAesthetic Retatrutide is intended to support research in metabolic health and weight management. As a triple-agonist peptide, it simultaneously mimics three natural hormones to suppress appetite, increase insulin sensitivity, and boost energy expenditure
. Early clinical data (Lilly) suggest it can significantly enhance fat loss and improve glycaemic markers: for example, one Phase 2 study reported mean weight losses up to 24.2% over 48 weeks at 12 mg dose
, and Phase 3 trials report up to 28.7% weight reduction at 68 weeks
. Concurrent improvements in blood pressure, lipids and other metabolic measures have also been observed
.
How Retatrutide Works
Retatrutide is a first-in-class triple receptor agonist
, meaning one molecule engages three key hormones. It binds strongly to:
GIP Receptors (GIPR): Enhances insulin secretion and sensitivity in response to meals.
GLP-1 Receptors: Reduces appetite, slows gastric emptying, and stabilises blood glucose.
Glucagon Receptors: Increases energy expenditure and fat oxidation.
By targeting all three pathways concurrently, Retatrutide amplifies weight loss and metabolic effects beyond those of single- or dual-agonist peptides
. In vitro assays confirm retatrutide’s high potency (EC₅₀ ~0.064 nM at human GIPR, 0.775 nM at GLP-1R)
. In animal models, repeated subcutaneous dosing produced “great body weight loss” and improved glucose tolerance
, consistent with its planned clinical uses.
Key Benefits (for Research Use Only)
Potent Weight Reduction: Dramatic body-weight loss (e.g. >22% in obesity trials
) and fat mass reduction.
Appetite Suppression: Enhanced satiety and reduced cravings (via GLP-1 and GIP effects).
Improved Glycaemic Control: Increased insulin sensitivity; in Phase 3 diabetes trials, Retatrutide lowered HbA1c by up to ~2.0% and body weight by ~16.8% at 40 weeks
.
Elevated Energy Expenditure: Glucagon activity drives higher metabolic rate and fat oxidation.
Comprehensive Metabolic Effects: Associated with reductions in blood pressure, lipids and liver fat (preliminary studies show up to ~82% liver fat reduction at 12 mg)
.
Research Insight: Ideal for studies on obesity, type 2 diabetes, fatty liver (MASLD), and related cardiovascular and sleep apnea models
.
Product Details
Brand: ChemAesthetic
Peptide: Retatrutide (synthetic triple-agonist)
Available Strengths: 10 mg / 30 mg (lyophilized powder)
Form: Sterile freeze-dried powder (requires reconstitution)
Kit Includes: 1 vial Retatrutide + 1 vial bacteriostatic water (2 ml)
Storage: Refrigerate vials (2–8°C) before reconstitution; see Storage below.
Regulatory: For laboratory and research use only. Not approved by MHRA/EMA/FDA
.
Usage & Dosage (Research)
Reconstitution: Add sterile bacteriostatic water to achieve a convenient concentration. For example, use 1 ml per 10 mg vial (resulting ~10 mg/ml)
. Gently swirl to dissolve; do not shake
.
Dosing: In animal or ex vivo studies, dosing must be determined by the investigator. For initial reference (not a prescription), one protocol suggests 1–2 mg once weekly (subcutaneously)
. Adjust incrementally as needed. In human trials, subjects were titrated to 9–12 mg weekly
. Use insulin syringes (100-unit) for accurate dosing. Always label clearly.
Handling: Wipe vial stopper with alcohol swab before drawing. Use aseptic technique. Prepare a fresh solution for each experimental session if needed.
Storage
Store the lyophilized vials at 2–8 °C until reconstitution. Once mixed, the solution can be kept refrigerated (2–8 °C) and used within 60 days
. Protect from light and avoid repeated freeze-thaw cycles.
Safety & Side Effects (Research Context)
In human trials, the safety profile of Retatrutide is similar to GLP-1 therapies
. The most common adverse events were gastrointestinal (nausea, diarrhea, vomiting, decreased appetite)
. Most GI effects were mild-to-moderate and often occurred during dose escalation
. Researchers should also monitor for effects related to rapid weight loss (electrolyte changes, nutrient deficiencies) as noted in clinical observations
. Because this is an investigational agent, all research use must comply with institutional and legal regulations. Observe proper safety protocols; this peptide is not for human consumption
.
FAQs
What is ChemAesthetic Retatrutide? A research-grade peptide (LY3437943) developed by Lilly as a triple GLP-1/GIP/glucagon agonist
. It is used in laboratory studies of metabolism and obesity. ChemAesthetic provides it as lyophilized 10 mg or 30 mg vials (sterile powder) with diluent. Not approved for patients; for research only.
How does Retatrutide compare to other peptides? Unlike GLP-1 analogues (e.g. semaglutide) or dual agonists (tirzepatide), Retatrutide activates three receptors simultaneously
. This triple-action has led to larger weight-loss effects in trials (~20–30% of body weight) than seen with older incretin drugs
.
What dosing should be used in research? There are no approved doses; investigators tailor protocols. In animal or in vitro work, one guide is 1–2 mg/week (SC) with stepwise titration
. In human trials, doses up to 9–12 mg/week were safely studied
. Ensure accurate reconstitution and dosing with precision syringes.
Are there any special storage instructions? Store vials refrigerated. Once diluted in bacteriostatic water, keep the solution at 2–8 °C and use within ~60 days
. Discard any unused solution after this period.
Is Retatrutide approved for use? No. Retatrutide is not approved by MHRA/EMA/FDA
. It is only available to researchers through experimental studies. Any claim of “approved” or clinical use is false. Always include a disclaimer: “For laboratory research use only. Not for human or veterinary use”
